Meta AnalysisID 683
外用壬二酸、水杨酸、烟酰胺和硫磺治疗痤疮 [Cochrane方案]
CRD42015020787
To assess the effects of topical treatments (azelaic acid, salicylic acid, nicotinamide, and sulphur) for acne.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 683
- Evidence Id
- 9241
- Core Evidence Id
- 9241
- Source Meta Analysis Id
- 662
- Herb2 Meta Analysis Id
- HBMA000662
- Crd Id
- CRD42015020787
- Title
- Topical azelaic acid, salicylic acid, nicotinamide, and sulphur for acne [Cochrane Protocol]
- Review Question
- To assess the effects of topical treatments (azelaic acid, salicylic acid, nicotinamide, and sulphur) for acne.
- Study Type Included
- We will consider all relevant randomised controlled trials (RCTs). Randomised trials with a cross-over design are eligible. We will exclude cluster-randomised trials and quasi-randomised trials (e.g. trials that allocate by using date of birth, case record number, or alternation).
- Condition Being Studied
- The Cochrane Skin Group
- Participant
- We will include participants with acne vulgaris who have been diagnosed based on clinical definition, regardless of age, gender, acne severity, and previous treatments. Studies will also be eligible where participants are diagnosed as having papulopustular, inflammatory, juvenile, or polymorphic acne. Except for neonatal and infantile acne, we will exclude trials in which participants have had a diagnosis of other subtypes of acne variants or acneiform eruptions as listed in Table 2.
- Animal
- Human Disease Modelled
- Intervention
- Topical azelaic acid, salicylic acid, nicotinamide, and sulphur with any treatment regimen, duration, dose, and delivery mode, compared with:<ol> any topical treatments; placebo; no treatment.</ol> The concomitant use of other topical or oral medications for acne vulgaris must be the same in both intervention arms.
- Comparator Control
- Any topical treatments; placebo; no treatment.
- Main Outcome
- <ol> Participants' global self assessment of acne improvement (e.g. measured by a four-point scale: excellent, good, fair, and poor). Withdrawal for any reason. </ol>
- Outcome Measure
- Additional Outcome
- <ol> Change in lesion counts (total or inflamed and non-inflamed separately). Physicians' global evaluation of acne improvement. Minor adverse events. Quality of life (QoL).</ol> Timing If possible, we will assess treatment effects by grouping the outcomes into short term (up to four weeks), medium term (from four to eight weeks) and long term (over eight weeks). Where there is more than one follow-up point within the same time period, we will use the latest one.
- Study Method
- Keyword
- Acne Vulgaris; Dicarboxylic Acids; Humans; Niacin; Niacinamide; Salicylic Acid; Sulfur
- Contact
- Hong Sang [email protected]
- Organisational Affiliation
- The Cochrane Collaboration http://www.cochrane.org/
- Funding Source
- The National Institute for Health Research (NIHR), Jinling Hospital, Nanjing, Zhejiang University, Hangzhou
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2015-05-22
- Anticipated Start Date
- 2014-11-15
- Anticipated Completion Date
- 2016-11-15
- Title Cn
- 外用壬二酸、水杨酸、烟酰胺和硫磺治疗痤疮 [Cochrane方案]
- Title En
- Topical azelaic acid, salicylic acid, nicotinamide, and sulphur for acne [Cochrane Protocol]
- Bilingual Status
- complete